Whole-Genome Sequencing for Resistance Level Prediction in Multidrug-Resistant Tuberculosis.
Aminoglycosides
/ therapeutic use
Antitubercular Agents
/ pharmacology
Bacterial Proteins
/ genetics
Drug Resistance, Multiple, Bacterial
/ genetics
Fluoroquinolones
/ pharmacology
Humans
Isoniazid
Microbial Sensitivity Tests
Mutation
Mycobacterium tuberculosis
Rifabutin
/ therapeutic use
Rifampin
/ pharmacology
Streptomycin
Tuberculosis, Multidrug-Resistant
/ drug therapy
minimal inhibitory concentration (MIC)
multidrug-resistant tuberculosis (MDR-TB)
resistance level
whole-genome sequencing (WGS)
Journal
Microbiology spectrum
ISSN: 2165-0497
Titre abrégé: Microbiol Spectr
Pays: United States
ID NLM: 101634614
Informations de publication
Date de publication:
29 06 2022
29 06 2022
Historique:
pubmed:
7
6
2022
medline:
2
7
2022
entrez:
6
6
2022
Statut:
ppublish
Résumé
Defining the precise relationship between resistance mutations and quantitative phenotypic drug susceptibility testing will increase the value of whole-genome sequencing (WGS) for predicting tuberculosis drug resistance. However, a large number of WGS data sets currently lack corresponding quantitative phenotypic data-the MICs. Using MYCOTBI plates, we determined the MICs to nine antituberculosis drugs for 154 clinical multidrug-resistant tuberculosis isolates from the Shenzhen Center for Chronic Disease Control in Shenzhen, China. Comparing MICs with predicted drug-resistance profiles inferred by WGS showed that WGS could predict the levels of resistance to isoniazid, rifampicin, streptomycin, fluoroquinolones, and aminoglycosides. We also found some mutations that may not be associated with drug resistance, such as EmbB D328G, mutations in the
Identifiants
pubmed: 35658579
doi: 10.1128/spectrum.02714-21
pmc: PMC9241708
doi:
Substances chimiques
Aminoglycosides
0
Antitubercular Agents
0
Bacterial Proteins
0
Fluoroquinolones
0
Rifabutin
1W306TDA6S
Isoniazid
V83O1VOZ8L
Rifampin
VJT6J7R4TR
Streptomycin
Y45QSO73OB
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0271421Références
Clin Microbiol Infect. 2022 May;28(5):731.e9-731.e15
pubmed: 34600118
Diagn Microbiol Infect Dis. 2016 Jun;85(2):177-81
pubmed: 27036978
Lancet Infect Dis. 2017 Mar;17(3):275-284
pubmed: 27919643
J Clin Microbiol. 2012 Jun;50(6):2085-8
pubmed: 22442316
Lancet Infect Dis. 2018 Apr;18(4):377
pubmed: 29582760
Antimicrob Agents Chemother. 2019 Mar 27;63(4):
pubmed: 30718257
N Engl J Med. 2018 Oct 11;379(15):1403-1415
pubmed: 30280646
J Clin Microbiol. 2016 Dec;54(12):2963-2968
pubmed: 27654338
PLoS Pathog. 2018 Oct 18;14(10):e1007297
pubmed: 30335850
Clin Microbiol Infect. 2004 Jul;10(7):662-5
pubmed: 15214882
J Clin Microbiol. 2014 Jun;52(6):2157-62
pubmed: 24740074
Sci Rep. 2018 Jun 26;8(1):9676
pubmed: 29946139
Mol Biol Evol. 2020 Jan 1;37(1):195-207
pubmed: 31532481
Clin Infect Dis. 2020 Jun 24;71(1):142-151
pubmed: 31504306
Curr Opin Pulm Med. 2011 May;17(3):134-41
pubmed: 21415753
PLoS One. 2013 Dec 11;8(12):e83012
pubmed: 24349420
J Clin Microbiol. 2017 Jun;55(6):1871-1882
pubmed: 28381603
Brief Bioinform. 2022 Mar 10;23(2):
pubmed: 35211720
Genome Med. 2019 Jun 24;11(1):41
pubmed: 31234910
Genome Med. 2015 May 27;7(1):51
pubmed: 26019726
J Antimicrob Chemother. 2013 Sep;68(9):2074-7
pubmed: 23633684